These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36553163)

  • 1. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial.
    Dotinga M; Vriens D; van Velden FHP; Stam MK; Heemskerk JWT; Dibbets-Schneider P; Pool M; Rietbergen DDD; de Geus-Oei LF; Kapiteijn E
    Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553163
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 3. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
    Worden F; Rajkovic-Hooley O; Reynolds N; Milligan G; Zhang J
    Endocrine; 2024 May; 84(2):663-669. PubMed ID: 38102498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
    Balmelli C; Railic N; Siano M; Feuerlein K; Cathomas R; Cristina V; Güthner C; Zimmermann S; Weidner S; Pless M; Stenner F; Rothschild SI
    J Cancer; 2018; 9(2):250-255. PubMed ID: 29344270
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer.
    Valerio L; Giani C; Agate L; Molinaro E; Viola D; Bottici V; Matrone A; Puleo L; Lorusso L; Cappagli V; Ribechini A; Elisei R
    Eur Thyroid J; 2021 Jul; 10(5):399-407. PubMed ID: 34540710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early prediction of treatment outcome for lenvatinib using
    Takeuchi S; Hirata K; Magota K; Watanabe S; Moku R; Shiiya A; Taguchi J; Ariga S; Goda T; Ohhara Y; Noguchi T; Shimizu Y; Kinoshita I; Honma R; Tsuji Y; Homma A; Dosaka-Akita H
    EJNMMI Res; 2023 Jul; 13(1):69. PubMed ID: 37460834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
    Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
    Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ahmaddy F; Burgard C; Beyer L; Koehler VF; Bartenstein P; Fabritius MP; Geyer T; Wenter V; Ilhan H; Spitzweg C; Todica A
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467085
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
    Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
    Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
    [No Abstract]   [Full Text] [Related]  

  • 15. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
    Dotinga M; Vriens D; van Velden F; Heijmen L; Nagarajah J; Hicks R; Kapiteijn E; de Geus-Oei LF
    Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):250-264. PubMed ID: 32744039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
    Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
    Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of lenvatinib treatment efficacy by using
    Takeuchi S; Shiga T; Hirata K; Taguchi J; Magota K; Ariga S; Gouda T; Ohhara Y; Homma R; Shimizu Y; Kinoshita I; Tsuji Y; Homma A; Iijima H; Tamaki N; Dosaka-Akita H
    BMJ Open; 2018 Aug; 8(8):e021001. PubMed ID: 30166292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.
    Capdevila J; Deandreis D; Durante C; Leboulleux S; Luster M; Netea-Maier R; Newbold K; Singer S; Sykiotis GP; Bartes B; Farnell K; Locati LD
    Eur Thyroid J; 2023 Aug; 12(5):. PubMed ID: 37429326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
    Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
    Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
    Mischler K; Kneifel S; Cathomas R
    Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.